Results 221 to 230 of about 20,950 (257)

Successful Treatment of Psoriasis in HIV with Secukinumab. [PDF]

Indian Dermatol Online J
Paul D, Banerjee S, Vasudevan B, Kishore K.   +3 more
europepmc   +1 more source

Dual Blocking of IL17A and IL36R for the Treatment of Refractory Hidradenitis Suppurativa: A Case Report. [PDF]

Biologics
Yu Y, Li J, Liu H, Sun Y, Zhang F.
europepmc   +1 more source

Induced pemphigus erythematosus after treatment for plaque psoriasis with secukinumab: a case report. [PDF]

Front Immunol
Hu F, Peng H, Gong J, Tao X, Wang X, Bao J, He P, Dirwanto L, Liu M, Yang H.   +9 more
europepmc   +1 more source

Dual impact of interleukin-17 A blockade on inflammatory and stromal pathways in peripheral spondyloarthritis. [PDF]

Arthritis Res Ther
Hammoura I, Fiechter RH, van Mens LJJ, de Jong HMY, Fluri IA, Tas SW, Baeten DLP, van de Sande MGH, Yeremenko NG.   +8 more
europepmc   +1 more source

Treatment of Secukinumab-induced Atopic Dermatitis-like Lesions Using Upadacitinib: A Case Report.

Indian J Dermatol
Xiang W, Lin X, Li Q, Zheng W.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Secukinumab

Reactions Weekly
  +13 more sources

Secukinumab

Reactions Weekly, 2019
  +11 more sources

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of Today, 2023
In recent years, the role of interleukin-17 (IL-17) in orchestrating and manipulating proinflammatory immune responses has received special attention.
T. Simopoulou, S. Tsiogkas, E. Zafiriou, D. Bogdanos   +3 more
semanticscholar   +1 more source